Showing 641 - 660 results of 104,399 for search '(( 2 fold decrease ) OR ( 5 ((we decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.44s Refine Results
  1. 641

    Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68. by Ines Cordeiro Filipe (5849144)

    Published 2022
    “…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
  2. 642
  3. 643

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…Compound <b>4f</b> exhibited potent EGFR inhibitory activity with an IC<sub>50</sub> value of 61 nM compared to that of Tamoxifen (IC<sub>50</sub> value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. Interestingly, <b>4f</b> showed remarkable PI3K/AKT/mTOR inhibitory activity with 0.18-, 0.27-, and 0.39-fold decrease in their concentration (reduction in controls from 6.64, 45.39, and 86.39 ng/mL to 1.24, 12.35, and 34.36 ng/mL, respectively). …”
  4. 644

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…Compound <b>4f</b> exhibited potent EGFR inhibitory activity with an IC<sub>50</sub> value of 61 nM compared to that of Tamoxifen (IC<sub>50</sub> value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. Interestingly, <b>4f</b> showed remarkable PI3K/AKT/mTOR inhibitory activity with 0.18-, 0.27-, and 0.39-fold decrease in their concentration (reduction in controls from 6.64, 45.39, and 86.39 ng/mL to 1.24, 12.35, and 34.36 ng/mL, respectively). …”
  5. 645
  6. 646
  7. 647

    Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

    Published 2019
    “…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
  8. 648

    The Type 2 Diabetes Risk Allele of <i>TMEM154</i>-rs6813195 Associates with Decreased Beta Cell Function in a Study of 6,486 Danes by Marie Neergaard Harder (232759)

    Published 2015
    “…Significant associations between <i>TMEM154</i>-rs6813195 and the beta cell measures insulinogenic index and disposition index and between <i>FAF1</i>-rs17106184 and 2-hour serum insulin levels were selected for further investigation in additional Danish studies and results were combined in meta-analyses including up to 6,486 Danes.</p><p>Results</p><p>We confirmed associations with type 2 diabetes for five of the seven SNPs (<i>TMEM154</i>-rs6813195, <i>FAF1</i>-rs17106184, <i>POU5F1/TCF19</i>-rs3130501, <i>ARL15</i>-rs702634 and <i>ABCB9/MPHOSPH9</i>-rs4275659). …”
  9. 649
  10. 650
  11. 651

    S5 Raw image - by Zhi Xuan Low (19270163)

    Published 2024
    “…This study also revealed a notable sequential reduction in serum levels of tumour markers, including carcinoembryonic antigen (CEA) and mouse Cytochrome P450 1A2 (CYP1A2), correlating with a significant decrease in tumour bulk volume upon treatment commencement. …”
  12. 652

    DataSheet2_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.pdf by Sunil Veeravalli (5074115)

    Published 2022
    “…<p>We previously showed that Fmo5<sup>−/−</sup> mice exhibit a lean phenotype and slower metabolic ageing. …”
  13. 653

    DataSheet1_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.PDF by Sunil Veeravalli (5074115)

    Published 2022
    “…<p>We previously showed that Fmo5<sup>−/−</sup> mice exhibit a lean phenotype and slower metabolic ageing. …”
  14. 654
  15. 655
  16. 656
  17. 657
  18. 658
  19. 659
  20. 660

    The Transition from a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk by Heba M Ismail (9568748)

    Published 2022
    “…Conclusions</p> <p>A transition from an increase to a decrease in AUC C-peptide approximately 1.5 years pre-diagnosis was validated in two independent cohorts. …”